Recent major breakthroughs in cancer immunotherapy, particularly the capacity of antibodies targeting the T cell inhibitory receptors PD-1 and CTLA-4 to induce sustained disease remission in a proportion of cancer patients, has renewed interest in the molecular understanding of tumor antigen presentation. This evidence concerns the gene CTLA4 and cancer.